Sundry Photography/iStock Editorial via Getty Images
Medtronic (NYSE:MDT) traded lower in the premarket on Tuesday after the MedTech giant, with its Q3 FY25 results, reaffirmed its full-year outlook despite a major opportunity to consolidate its lead in the market for pulse field ablation systems following a setback